Protocolo diagnóstico de las alteraciones leucocitarias en la artritis reumatoide

  1. Pretel Ruiz, P.
  2. Barrio Nogal, L.
  3. Emperiale, V.E.
  4. Romero Bogado, M.L.
  5. Pérez Gómez, A.
  6. Álvarez-Mon Soto, M.
Zeitschrift:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Datum der Publikation: 2017

Titel der Ausgabe: Enfermedades del sistema inmune y reumatológicas (V) Artritis reumatoide, síndrome de Sjögren y uveítis

Serie: 12

Nummer: 28

Seiten: 1666-1671

Art: Artikel

DOI: 10.1016/J.MED.2017.02.016 DIALNET GOOGLE SCHOLAR

Andere Publikationen in: Medicine: Programa de Formación Médica Continuada Acreditado

Zusammenfassung

Introduction Patients with RA can present a wide variety of hematological disorders. Classification Within leukocyte alterations we can find three groups: leukopenia, leukocytosis and lymphoproliferative disorders. Among the leukopenias, there is the Felty syndrome, which is the most frequent and consists of the triad of neutropenia, splenomegaly and RA; LGL leukemia, which is a proliferation of large granular lymphocytes associated with neutropenia and drug-induced neutropenia, since most of the agents used for treating RA can induce it (methotrexate, cyclophosphamide...). In the presence of leukocytosis, RA can develop neutrophilia in the context of an inflammation or an associated bacterial infection, or eosinophilia, which is related to greater extra-articular involvement. Lymphoproliferative disorders have a higher occurrence in these patients, with an incidence and mortality due to leukemia and lymphoma which doubles the expected values, mainly in those patients with long-term arthritis.

Bibliographische Referenzen

  • Saway PA, Prasthofer EF, Barton JC. Prevalence of granular lymphocyte proliferation in patients with rheumatoid arthritis and neutropenia. Am J Med. 1989;86(3):303.
  • Huskisson EC. Azathioprine. Clin Rheum Dis. 1984;10(2):325.
  • Woodson LC, Dunnette JH, Weinshilboum RM. Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther. 1982;222(1):174.
  • Hastings R, Ding T, Butt S, Gadsby K, Zhang W, Moots RJ. Neutropenia in patients receiving antitumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010;62(6):764.
  • Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20(2):119.
  • Amari W, Zeringue AL, McDonald JR, Caplan L, Eisen SA, Ranganathan P. Risk of non melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford). 2011;50(8):1431.
  • Dreyer L, Mellemkjær L, Andersen AR, Bennett P, Poulsen UE, Juulsgaard Ellingsen T. Incidences of overall and site specific cancers in TNF inhibitor treated patients with rheumatoid arthritis and other ar-thritides - a follow-up study from the DANBIO Registry. Ann Rheum Dis. 2013;72(1):79-82.
  • Raaschou P, Simard JF, Holmqvist M, Askling J; ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013;346:f1939.
Fuente de los datos: Dialnet